Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 58 recommendations for 52 medicines and 3 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
6.4. Antiviral medicines
  1. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  2. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  3. Aciclovir General information
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Indications
    Zoster Varicella Herpes simplex infections
  4. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  5. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)
    Indications
    Chronic hepatitis C
  6. Daclatasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 60 mg + 400 mg
    Indications
    Chronic hepatitis C
  7. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  8. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  9. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  10. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  11. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  12. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  13. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
  14. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  15. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 20 mg granules
    • Oral > Solid > tablet: 100 mg + 40 mg
    Indications
    Chronic hepatitis C
  16. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  17. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  19. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  20. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  21. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
    • Oral > Solid > dosage form: 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  22. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > dispersible tablet: 50 mg
    • Oral > Solid > tablet: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  23. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  24. Raltegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  25. Ravidasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  26. Ribavirin General information
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Viral haemorrhagic fever, not elsewhere classified
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  27. Ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  28. Sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
    Chronic hepatitis C
  29. Sofosbuvir + velpatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
    Indications
    Chronic hepatitis C
  30. Tenofovir disoproxil fumarate General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  31. Valaciclovir General information
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella Therapeutic equivalent to aciclovir for Herpes simplex infections
  32. Valganciclovir General information
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL powder for oral solution
    • Oral > Solid > tablet: 450 mg
    Indications
    Cytomegaloviral retinitis
  33. Zidovudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > tablet: 300 mg
    • Oral > Solid > capsule: 250 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified